Sponsored By
Gastrointestinal (GI) infections remain a common cause of illness (1), yet overlapping symptoms and diverse etiologies can complicate timely diagnosis and treatment (2). Laboratories are being asked to deliver faster, more definitive answers — without adding complexity to already stretched workflows. The Xpert® GI Panel is designed to meet that need with a single, multiplex PCR test built for clarity and efficiency.
Xpert® GI Panel is a multiplex, sample to answer PCR test that identifies 11 clinically relevant GI pathogens — bacterial, viral, and parasitic — from a single stool sample. Its design reflects a targeted approach: covering high value pathogens implicated in acute gastroenteritis, while avoiding organisms with negligible impact on clinical management or high rates of colonization which increase rates of co-detection that complicates interpretation (3).
Traditional diagnostic workups can involve culture, antigen tests, microscopy, and multiple specimen collections. These methods are time consuming and labor-intensive. Sensitivity also varies across techniques. Delayed results can contribute to unnecessary imaging, empiric antibiotic use, and extended isolation days (4).
The panel runs on GeneXpert® systems with 10-color technology that enables multiplex detection of 10 or more PCR targets. GeneXpert systems automate sample extraction, nucleic acid amplification, and detection, with a load-and-go workflow that requires less than 1 minute of hands on time.
The panel consolidates multi day, multi method investigations into a single standardized workflow. With timely and appropriate diagnostic testing, labs can potentially reduce culture burden and multiple reflex assays, and lessen reliance on microscopy specific expertise. The simple workflow is designed to help streamline operations with convenient on demand testing. And for clinicians relying on lab outputs, clinically relevant information can guide isolation decisions and promote antimicrobial stewardship, allowing teams to respond promptly to suspected outbreaks and high-risk cases.
Industry Insights articles are created and paid for by advertisers. The views expressed in these articles do not necessarily represent ADLM's views, and their inclusion in CLN is not an endorsement by CLN or ADLM.